Navigation Links
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Date:7/30/2008

chiatry at Saint Louis University School of Medicine, and the lead investigator who presented the data. "These findings reinforce the safety, tolerability and efficacy of memantine in a newly-developed once-a-day formulation."

Marco Taglietti, MD, Executive Vice President and Chief Medical Officer at Forest added, "With this novel formulation, the efficacy and tolerability of Namenda is delivered in a more convenient, once-daily dose."

About the Study

A randomized, double-blind, placebo-controlled trial of 677 outpatients already taking a cholinesterase inhibitor was conducted in multiple centers in the United States, Argentina, Chile, and Mexico. Patients in the 24-week study were randomly assigned to receive either 28 mg/day of memantine once-daily extended-release or placebo. The primary endpoints evaluated were change from baseline on the Severe Impairment Battery (SIB) and the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) rating at week 24. The study showed statistically significantly higher cognitive abilities, as measured by the SIB, and clinical global status, as measured by the CIBIC-Plus, in patients treated with memantine 28 mg once-daily extended-release compared to placebo (p=0.001 for SIB and p=0.008 for CIBIC-Plus, both using pre-defined last observation carried forward analyses). The CIBIC-Plus is a global measure of a patient's overall status evaluating cognition, behavior, and activities of daily living.

Results for a secondary endpoint and additional assessment variables reinforced the positive findings seen with the primary endpoints. Assessments were conducted to evaluate change in behavior from baseline using the Neuropsychiatric Inventory (NPI) at 24 weeks and change in verbal fluency from baseline using the Verbal (Semantic) Fluency Test at 24 weeks. Memantine provided significant benefits over placebo (p=0.005 for NPI and p=0.004 for verbal fluency). Measurement of daily living
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Focal Cryoablation Highlighted in Urology Times Best of AUA Orlando 2008
2. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
3. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
4. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
5. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
6. New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
7. Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
11. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
... today announced the submission of a supplemental New ... Administration (FDA) for SEROQUEL XR(TM),(quetiapine fumarate) Extended-Release Tablets ... disorder (GAD), including maintenance of,antianxiety effect. It is ... an,atypical antipsychotic medicine in GAD. The submission is ...
Cached Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
(Date:8/28/2014)... (BRONX, NY) Researchers from Albert Einstein College of ... a potential antibody therapy for Sudan ebolavirus (SUDV), one of ... the Zaire ebolavirus (EBOV), is now devastating West Africa. First ... (most recently in 2012) that have killed more than ... ACS Chemical Biology . , Between 30 and 90 ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... a Chinese herbal medication practitioner in Melbourne for ... a team of intensive care and emergency physicians ... who prescribe complementary medications. , Writing in ... Australasian College for Emergency Medicine, emergency medicine trainees ... the Intensive Care Unit at the Royal Melbourne ...
(Date:8/28/2014)... New York, New York (PRWEB) August 28, 2014 ... continue to mount in courts around the U.S., Bernstein ... & Gynecology is touting devices like Mirena as ideal ... from The Daily Press, the authors of the study ... comes to preventing pregnancy than other methods favored by ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
... a booster vaccination against H5N1 avian influenza given years after ... controlling a potential future pandemic. The study is published ... Infectious Diseases, now available online. , H5N1 continues to ... of mid-June, more than 60 percent of the more than ...
... ADDitude magazine,s top scientific,advisors investigate and explain non-drug ... green time and neurofeedback -,that may relieve ADHD ... how,nutrition, exercise and supplements can help treat ADHD ... magazine, the leading,publication for families and adults living ...
... boost,disability field,s quest to tie in public funding ... 16 One of the most complex,issues in ... and fund,services equitably to people with intellectual and ... Intensity Scale (SIS),assessment tool, developed by the American ...
... days of summer are here, and,for many, the rising ... an,estimated 40 percent of children and 20 percent of ... are spending three billion,dollars a year on antihistamines, often ... say in-vitro blood tests, the,latest generation of allergy tests, ...
... to irregular patterns of light and darkness can cause ... with the 24-hour solar day, negatively affecting human health ... the relationship between circadian disruptions and human maladies. ... Institute,s Lighting Research Center (LRC) provides a new framework ...
... Amsterdam, 16 July 2008 Elsevier, a leading publisher of ... Urology , the official journal of the European Association ... 5.634. , European Urology (also ... papers, fast response and an international profile. To keep up ...
Cached Medicine News:Health News:Booster vaccination may help with possible future avian influenza pandemic 2Health News:Booster vaccination may help with possible future avian influenza pandemic 3Health News:Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments 2Health News:The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals 2Health News:New approach sheds light on ways Circadian disruption affects human health 2Health News:New approach sheds light on ways Circadian disruption affects human health 3
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: